Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus insulin with add-on dapagliflozin, sitagliptin, or pioglitazone in type 2 diabetes
ChiCTR1800016902Phase 4Not yet recruiting
- Sponsor
- Chongqing Armed Police Hospital
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin Group, Dapagliflozin Group and Pioglitazone Group (3 arms). Primary endpoints: Glycosylated hemoglobin and Composite goal attainment. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
dapagliflozinsitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800016902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016902.